Score Breakdown
Trash.
Pulse Biosciences is a speculative, pre-revenue medical device company trading at a $1.3B market cap with under $1M in annual revenue and $70M+ in annual cash burn. The investment thesis is entirely predicated on the success of its nsPFA cardiac catheter in a pivotal trial that hasn't yet completed enrollment, with FDA approval and meaningful commercialization 3-5 years away. Meanwhile, the company faces competition from Medtronic and Boston Scientific in the PFA space, has negative gross margins on its only commercial product, requires imminent dilutive capital raises, and is governed by a structure heavily dependent on a single insider (Duggan owning ~88% of a rights offering). The 96% European feasibility success rate is encouraging but early-stage, and the stock price already reflects near-perfect execution. At 3,700x revenue, even optimistic scenarios struggle to justify the current valuation, making this a clear overvaluation with binary trial risk.
Negative cash flow. Can't value it.
Some yellow flags.
Minimal.
Neutral.
Tight but ok.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The core bear thesis rests on an extreme valuation mismatch: the company maintains a ~$1.4 billion market cap while generating less than $1 million in annual revenue. With a quarterly cash burn of ~$14.6 million and a widening net loss of $72.8 million for FY2025, the company faces significant execution risk. Skeptics argue that current prices already bake in perfect outcomes for the NANOPULSE-AF and NANOCLAMP-AF clinical trials, leaving no margin for error or the likely high costs of large-scale commercialization. (Sources: Simply Wall St, AlphaStreet)
🔍 What's In The SEC Filings
The provided data is strictly metadata and lacks the financial substance required for a comprehensive forensic risk assessment.
Zero-Value Disclosure Items
“Document Information [Line Items]: ['']”
The filing provides headers but lacks specific material disclosures under Item 2.02 or Item 8.01, rendering it a shell document.
Future-Dated Reporting
“Document, Period End Date: ['May 04, 2026']”
The filing is dated in the future relative to current real-time, which may indicate a template error or a simulated data set.
Valuation remains speculative; the lack of Itemized disclosures prevents adjustment of intrinsic value models.
The shift of the entity address to Miami (Brickell Key) may indicate a change in corporate footprint, though without financial context, the impact is speculative.